Renquan Zhang

Renquan Zhang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2019 in Disease Markers
Verified
Journal Article
Open access
PDF file
LYLong Yao
Long Yao
MLMengke Liu
Mengke Liu
YHYunlong Huang
Yunlong Huang
KWKaiming Wu
Kaiming Wu
XHXin Huang
Xin Huang
RZRenquan Zhang
Renquan Zhang
Background. Antidiabetic medications (ADMs) can alter the risk of different types of cancer, but the relationship between lung cancer incidence and metformin remains controversial. Our aim was to quantitatively estimate the relationship between incidences of lung cancer and metformin in patients with diabetes in this meta-analysis. Methods. We performed a search in PubMed, Embase, ISI Web of Science, and Cochrane Library until September 20, 2017. The odds ratio (OR), relative risk (RR) or hazard ratio (HR), and 95% confidence interval (95% CI) were estimated using the random-effect model. The Newcastle-Ottawa Scale (NOS) was used to assess the study quality. Results. A total of 13 studies (10 cohort studies and 3 case-control studies) were included in the meta-analysis. Compared to nonmetformin users, metformin probably decreased lung cancer incidence in diabetic patients (RR=0.89; 95% CI, 0.83-0.96; P=0.002) with significant heterogeneity (Q=35.47, I2=66%, P=0.0004). Subgroup analysis showed that cohort studies (RR=0.91; 95% CI, 0.85-0.98; P=0.008), location in Europe (RR=0.90; 95% CI, 0.86-0.94; P<0.0001), the control drug of the sulfonylurea group (RR=0.91; 95% CI, 0.86-0.96; P=0.001), and adjusting for smoking (RR=0.86; 95% CI, 0.75-1.00; P=0.05) may be related to lower lung cancer risk. No significant publication bias was detected using a funnel plot. Conclusion. Metformin use was related to a lower lung cancer risk in diabetic patients compared to nonusers, but this result was retrieved from observational studies and our findings need more well-designed RCTs to confirm the association.

10 January 2023 in Frontiers in Genetics
Verified
Journal Article
Open access
WLWen-Jian Liu
Wen-Jian Liu
YZYuan Zhao
Yuan Zhao
XCXu Chen
Xu Chen
MMMan-Li Miao
Man-Li Miao
RZRenquan Zhang
Renquan Zhang
Esophageal cancer is a widespread cancer of the digestive system that has two main subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EA). In the diverse range of cancer therapy schemes, the side effects of conventional treatments remain an urgent challenge to be addressed. Therefore, the pursuit of novel drugs with multiple targets, good efficacy, low side effects, and low cost has become a hot research topic in anticancer therapy. Based on this, epigenetics offers an attractive target for the treatment of esophageal cancer, where major mechanisms such as DNA methylation, histone modifications, non-coding RNA regulation, chromatin remodelling and nucleosome localization offer new opportunities for the prevention and treatment of esophageal cancer. Recently, research on epigenetics has remained at a high level of enthusiasm, focusing mainly on translating the basic research into the clinical setting and transforming epigenetic alterations into targets for cancer screening and detection in the clinic. With the increasing emergence of tumour epigenetic markers and antitumor epigenetic drugs, there are also more possibilities for anti-esophageal cancer treatment. This paper focuses on esophageal cancer and epigenetic modifications, with the aim of unravelling the close link between them to facilitate precise and personalized treatment of esophageal cancer.

1 October 2021 in Biochemistry and Cell Biology
Verified
Journal Article
Closed access
CLChen Lu
Chen Lu
GNGuangyao Ning
Guangyao Ning
PSPanpan Si
Panpan Si
CZChunsheng Zhang
Chunsheng Zhang
WLWenjian Liu
Wenjian Liu
SGShenglin Ge
Shenglin Ge
Lung cancer is the leading cause of cancer-related death globally. Ubiquitin modification plays a crucial role in the regulation of gene expression, and is closely associated with cancer pathogenesis. The aim of our study was to clarify the role and mechanisms of action for HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 (HECW1) in non-small cell lung cancer (NSCLC). Herein, we demonstrate that the expression of HECW1 was significantly increased in NSCLC cell lines and tissues. Upregulation of HECW1 markedly enhanced the proliferation of NSCLC cells, whereas downregulation of HECW1 significantly inhibited proliferation. Moreover, the expression levels of HECW1 positively correlated with the migration and invasiveness of NSCLC cells. Upregulation or downregulation of HECW1 only affected the protein expression levels of SMAD family member 4 (Smad4), but had no effect on the mRNA expression levels. Furthermore, after treatment with MG-132, the relative protein level of Smad4 significantly increased in NSCLC cells. HECW1 promoted the proliferation, migration, and invasiveness of NSCLC cells by inducing the ubiquitination and degradation of Smad4, thus our data provide a novel target for NSCLC treatment.

21 July 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
HLHui Liang
Hui Liang
GLGaoli Liu
Gaoli Liu
QFQinglu Fan
Qinglu Fan
ZNZhihao Nie
Zhihao Nie
SXSongping Xie
Songping Xie
RZRenquan Zhang
Renquan Zhang

1 June 2021 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
HZHao Zheng
Hao Zheng
NKNingning Kang
Ningning Kang
YHYunlong Huang
Yunlong Huang
YZYuan Zhao
Yuan Zhao
RZRenquan Zhang
Renquan Zhang
Background: Esophagectomy is the standard treatment for early-stage esophageal cancer but is associated with high morbidity and mortality. Thus, endoscopic resection is increasingly used as an alternative option. However, the literature is inconsistent regarding the efficacy of these treatments. This meta-analysis aimed to compare the efficacy and safety of these two treatments. Methods: A systematic electronic search of PubMed, EMBASE, and the Cochrane Library was performed for studies comparing endoscopic resection and surgery for early-stage esophageal cancer. The overall survival, tumor recurrence, major adverse events, procedure-related mortality, and R0 resection rates were investigated. Forest plots were constructed based on the random-effects model. Results: We found 15 studies involving 2,467 and 2,264 patients who underwent endoscopic resection and surgery, respectively. The meta-analysis showed that patients undergoing endoscopic resection had significantly fewer major adverse events (relative risk, 0.46; 95% confidence interval, 0.33–0.64) and a lower procedure-related mortality rate (relative risk, 0.27; 95% confidence interval, 0.10–0.73) than those undergoing surgery. The number of postprocedural stricture events did not significantly differ between the two treatments (relative risk, 0.89; 95% confidence interval, 0.53–1.49). Endoscopic resection was associated with higher recurrence rates (relative risk, 1.69; 95% confidence interval, 0.99–2.89) and lower R0 resection rates (relative risk, 0.92; 95% confidence interval, 0.86–0.98) than surgery. There may be some advantage conferred by esophagectomy in the long-term survival outcomes (hazard ratio, 1.21; 95% confidence interval, 1.02–1.43). Discussion: Endoscopic resection is a minimally invasive and safe treatment for early-stage esophageal cancer. However, esophagectomy may be associated with better long-term survival.

1 December 2012 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
RZRenquan Zhang
Renquan Zhang
WXWan-Li Xia
Wan-Li Xia
NKNing-Ning Kang
Ning-Ning Kang
WGWei Ge
Wei Ge
ACAn-Guo Chen
An-Guo Chen
KZKe-Chao Zhu
Ke-Chao Zhu